ClinicalTrials.gg
CompletedNCT03478371Updated Aug 26, 2019Results posted

In-use Study of Four Different Tampons

An interventional study of tampon D and tampon M in Menstruation, sponsored by Procter and Gamble. Completed at 1 site in United States. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-26.

Sponsored by Procter and Gamble · Not applicable, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Female
01

Study summary

This study will evaluate the impact on vaginal health of four different tampons using gynecologic assessment and subjective assessment of comfort during in-use conditions

02

Conditions studied

  • Menstruation

Keywords

  • tampon
03

In context

Lead sponsor

Procter and Gamble is the lead sponsor of 83 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: To be considered eligible for enrollment into this study subjects must meet the following criteria:

  1. signed the ;
  2. female, between 18 and 55 years of age;
  3. agree to practice abstinence or use an effective form of (e.g. intrauterine device, oral contraceptives, contraceptive implants or injections, diaphragm with spermicide, cervical cap, or constant use of condom) for at least the past 4 months and willing to continue throughout the study or have had a tubal ligation or your partner has had a vasectomy at least 4 months before being enrolled in the study;
  4. be in generally good health without disease as determined by investigator or designee based on medical history and vaginal exam;
  5. for at least the last 4 months, have a consistent menstrual cycle lasting 21-35 days with menstrual bleeding lasting at least 3 days' duration;
  6. primarily use tampons for their feminine protection needs during their periods (may use provided pads and/or pantiliners as back-up to tampon);
  7. typically use Regular (6-9 grams) absorbency tampons for the majority of their period,
  8. wears tampons during menstruation with no history of abnormal discomfort;
  9. last pap smear was normal in the past 3 years or a normal pap with a negative HPV in the past 5 years (age 18-21 does NOT need a PAP if they have never been sexually active), per standard of care (per ACOG guidelines), (self-reported);
  10. agree to refrain from vaginal intercourse within 48 hours of each vaginal exam scheduled visit;
  11. agree to refrain from showering within twelve (12) hours or bathing within twenty-four (24) hours (1 day) of each visit (except Visit 2);
  12. agree to refrain from using douching substances, feminine hygiene products, and to not apply powders, perfumes, wipes, lotions, creams, or emollients to their genital area 48 hours prior to the screening visit and through the completion of the study, if accepted to participate in the study;
  13. agree to refrain from taking anti-inflammatory, antihistamine and/or, systemic and/or topical, (including new hormonal contraceptives) medications until they have completed the study (e.g. Advil, Motrin, Benadryl, etc.);
  14. agree to only use the tampons, pads and pantiliners supplied at each study visit for her menstrual protection while participating in this study;
  15. be willing and able to comply with the study requirements;
  16. agree to complete all study questionnaires;
  17. agree to refrain from participation in other concurrent clinical research studies;
  18. agree to refrain from genital hair removal (e.g. waxing/shaving, etc.) while on the study;
  19. agree to refrain from using antibacterial body soap while on the study (e.g. Safeguard)

Exclusion Criteria: Subjects will be excluded from the study if they meet any of the following criteria:

  1. have a menstrual abnormality with in the last 4 months (such as oligomenorrhea or amenorrhea);
  2. has had a vaginal delivery in the last 6 months;
  3. had vaginal surgery, perineal surgery, uterine surgery, miscarriage or abortion in the last 6 months;
  4. are pregnant (per urine pregnancy test at screening), or intend to become pregnant in the next 5 months;
  5. have a history of Toxic Shock Syndrome (TSS);
  6. have a history of heart valve replacement;
  7. have had an abnormal Pap in either of your last 2 Pap Smears;
  8. have taken steroids (systemic and/or topical), corticosteroids, antihistamines, and/or anti-inflammatories within the past seven days (excludes hormonal contraception);
  9. have a history of drug therapy, chemotherapy, or radiation therapy;
  10. have uncontrolled and/or unstable diabetes (exception...stable dose of Diabetic medication for at least 6 months prior to enrollment) in the opinion of the Investigator;
  11. have a vulvar piercing;
  12. have a history of genital herpes;
  13. within the last 6 months have had endometrial disease/uterine fibroids with symptoms of heavy menstrual flow (super plus tampon absorbency use) and/or severe menstrual cramping;
  14. have you been diagnosed with a current medical condition which might compromise the immune system functions; including cancer, anemia, leukopenia, leukocyte function deficiency, malnutrition, or chemical dependence (e.g. opiates, marijuana etc.) (self-reported);
  15. have clinically diagnosed genital warts, lesions, and/or vaginal infections (such as bacterial vaginosis (BV), Candida spp., Trichomonas vaginalis) at the screening visit;
  16. have clinically diagnosed active or vaginal infections (Chlamydia trachomatis and/or Neisseria gonorrhoeae) identified through lab results from the microbiological sample obtained at the screening visit;
  17. has urinary incontinence which causes subject to regularly use and saturate diapers or absorbent panties or pads more than 3 times a week over the last 4 months, or currently under treatment for a pelvic floor disorder (i.e., perineal floor re-education with vaginal probe within last 6 months);
  18. have history of or current diagnosis of AIDS/, organ transplant, neoplasia, liver disease, renal disease, deep vein thrombosis, pulmonary embolism, haemophilia, neutropenia, disease, major depression or any other medical condition, which in the opinion of the Investigator would preclude study participation (exception...stable dose of Thyroid medication for at least 6 months prior to enrollment);
  19. having a vaginal probiotic therapy (self-reported)
  20. have participated in a clinical study with exposure to any drug product within 30 days prior to this study;
  21. have a vaginal erythema grade of ≥2.0 and/or the presence of abrasions and/or ulcerations as determined by investigator, at the screening visit;
  22. have taken antibiotics or antifungals within last 4 weeks (Topical use of antibiotics or antifungals outside the perineal/genitourinary area is allowed at the discretion of the Investigator);
  23. have started a new hormonal birth control in the previous 4 months or plan changing hormonal birth control throughout the study period;
  24. currently experiencing bladder, uterine or rectal prolapse (investigator to verify at screening visit).
  25. history of led or laser vaginal therapy within last 6 months (self-reported)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
94 participants (actual)

Study arms

  • Sham comparator
    Marketed Tampon D

    Regular absorbency tampon

    Device: tampon D

  • Sham comparator
    Marketed Tampon M

    Regular absorbency tampon

    Device: tampon M

  • Sham comparator
    Marketed Tampon T

    Regular absorbency tampon

    Device: tampon T

  • Sham comparator
    Marketed Tampon V

    Regular absorbency tampon

    Device: tampon V

Interventions

  • Devicetampon D

    regular absorbency tampon

  • Devicetampon M

    regular absorbency tampon

  • Devicetampon T

    regular absorbency tampon

  • Devicetampon V

    regular absorbency tampon

06

What researchers measure

Primary outcomes

  1. Tolerance of Tampon Wear Via Physician Assessment of Vaginal Health

    The physician examiner determined tampon tolerance based on the following: 1) Vaginal erythema (0-4 scale), 2) vaginal lacerations (presence or absence), 3) vaginal abrasions (presence or absence), 4) vaginal pH, 5) vaginal discharge

    Time frame: within 72 hours last tampon use

  2. Vaginal pH

    Vaginal pH

    Time frame: within 72 hours last tampon use

Secondary outcomes

  1. Subject Comfort Diary

    Diary assessment of tampon wear comfort. This assessment uses a 5-point scale which was summarized using the mean as the summary statistic. This questionnaire measured overall comfort using a +2 to -2 scale that was converted to a 0 to 100 scale: 100 = excellent rating and 0 =poor rating

    Time frame: 4 months

  2. Subject Comfort Questionnaire

    Post-menstruation assessment of tampon wear comfort. This assessment uses a 5-point scale which was summarized using the mean as the summary statistic. This questionnaire measured overall satisfaction using a +2 to -2 scale that was converted to a 0 to 100 scale: 100 = excellent rating and 0 = poor rating

    Time frame: 4 months

07

Results

Posted Aug 26, 2019

Participant flow

Participant flow — Overall Study
MilestoneOverall Study
Started94
Received tampon d91
Received tampon m92
Recived tampon t90
Received tampon v91
Completed89
Not completed5
Withdrew: Non-compliance1
Withdrew: Lost to follow-up4

Outcome measures

PrimaryTolerance of Tampon Wear Via Physician Assessment of Vaginal Health

The physician examiner determined tampon tolerance based on the following: 1) Vaginal erythema (0-4 scale), 2) vaginal lacerations (presence or absence), 3) vaginal abrasions (presence or absence), 4) vaginal pH, 5) vaginal discharge

Time frame:
within 72 hours last tampon use
Reported as:
Count of participants · Participants
Tolerance of Tampon Wear Via Physician Assessment of Vaginal Health
ParticipantsMarketed Tampon DMarketed Tampon MMarketed Tampon TMarketed Tampon V
Erythema score greater than 00000
Presence of Ulcerations0000
Presence of Abrasions0000
Abnormal Vaginal Discharge0000
PrimaryVaginal pH

Vaginal pH

Time frame:
within 72 hours last tampon use
Reported as:
Mean · pH
Vaginal pH
pHMarketed Tampon DMarketed Tampon MMarketed Tampon TMarketed Tampon V
Vaginal pH4.43 ± 0.0534.46 ± 0.0614.40 ± 0.0554.44 ± 0.061
SecondarySubject Comfort Diary

Diary assessment of tampon wear comfort. This assessment uses a 5-point scale which was summarized using the mean as the summary statistic. This questionnaire measured overall comfort using a +2 to -2 scale that was converted to a 0 to 100 scale: 100 = excellent rating and 0 =poor rating

Time frame:
4 months
Reported as:
Mean · units on a scale
Subject Comfort Diary
units on a scaleMarketed Tampon DMarketed Tampon MMarketed Tampon TMarketed Tampon V
Subject Comfort Diary81.7 ± 2.6078.5 ± 2.5674.0 ± 2.5873.2 ± 2.57
SecondarySubject Comfort Questionnaire

Post-menstruation assessment of tampon wear comfort. This assessment uses a 5-point scale which was summarized using the mean as the summary statistic. This questionnaire measured overall satisfaction using a +2 to -2 scale that was converted to a 0 to 100 scale: 100 = excellent rating and 0 = poor rating

Time frame:
4 months
Reported as:
Mean · units on a scale
Subject Comfort Questionnaire
units on a scaleMarketed Tampon DMarketed Tampon MMarketed Tampon TMarketed Tampon V
Subject Comfort Questionnaire78.4 ± 3.1771.5 ± 3.1766.5 ± 3.1760.9 ± 3.15

Adverse events

Collected over six months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Marketed Tampon D0/91 (0%)1/91 (1.1%)0/91 (0%)
Marketed Tampon M0/92 (0%)0/92 (0%)0/92 (0%)
Marketed Tampon T0/90 (0%)0/90 (0%)0/90 (0%)
Marketed Tampon V0/91 (0%)0/91 (0%)0/91 (0%)
Most frequent serious events
Most frequent serious events
EventMarketed Tampon DMarketed Tampon MMarketed Tampon TMarketed Tampon V
Post-traumatic stress disorderPsychiatric disorders1/910/920/900/91

Baseline characteristics

Age, Continuous
Age, Continuous(years)Overall Study
Mean33.4 (18 to 49)
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female94
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Study
Hispanic or Latino2
Not Hispanic or Latino92
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Overall Study
American Indian or Alaskan Native2
Asian Indian0
Asian Oriental2
Black36
Caucasian51
Mutli-racial0
Native Hawaiian or Pacific Islander0
Other3
08

Study locations

1 site
  • Synexus-US
    Cincinnati, Ohio 45236, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Jul 2018, 6 months.

Results were first posted in Aug 2019, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2018
First posted
Mar 27, 2018
StartActual
Jan 16, 2018
Primary completionActual
Jul 18, 2018
CompletionActual
Jul 18, 2018
Results first posted
Aug 26, 2019
Last update
Aug 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03478371
Lead sponsor
Procter and Gamble
Responsible party
Sponsor
First posted
Mar 27, 2018
Start date
Jan 16, 2018
Primary completion
Jul 18, 2018
Completion
Jul 18, 2018
Results posted
Aug 26, 2019
Last update
Aug 26, 2019

Study contacts

Michael Noss, MD
principal investigator · Site Medical Director

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion